- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03478020
Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study (DDI-COC)
Open-Label, Fixed-Sequence 3-Period Study to Determine the Effects of Repeated Oral Dosing of AQX-1125 on the Pharamacokinetics, Safety and Tolerability of a Combination Oral Contraceptive in Healthy Female Subjects
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
-
Groningen, Nederland
- PRA Health Sciences - Early Development Serices
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Aged 18-45 years, inclusive, at time of signing Informed Consent
- Adult females of child bearing potential, who are non-pregnant and non-lactating, and must agree to use adequate additional contraception from the start of Treatment Period A until 90 days after the last dose of AQX-1125
- BMI 18.0 - 35.0 kg/m2
- Good physical and mental health based on medical history, physical examination, clinical laboratory, ECG and vital signs, as judged by the investigator
Exclusion Criteria:
- Previous participation in the current study
- Any clinically significant history of breakthrough bleeding
- Using tobacco or other nicotine containing products within 12 months prior to the first study-specific COC-cycle intake
- History of alcohol abuse or drug addiction
- Positive drug and alcohol screen at screening and (each) admission to the clinical research center
- Average intake of more than 24 units of alcohol per week
- Positive screen for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies or anti-human immunodeficiency virus (HIV) 1 and 2 antibodies
- Participation in a drug study within 30 days prior to screening. Participation in more than 2 other drug studies in the 10 months prior to (the first) drug administration in the current study
- Donation or loss of more than 100 mL of blood within 60 days prior to the start of Treatment Period A, on Day 1. Donation or loss of more than 1.0 liters of blood in the 10 months prior to the start of Treatment Period A, on Day 1
- Significant and/or acute illness within 5 days prior to Day 1 in Treatment Period A, that may impact safety assessments, in the opinion of the investigator
- Unsuitable veins for blood sampling
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Pre-Treatment, Treatment Cycles A & B
Pre-Treatment: Two cycles of a combined oral contraceptive (COC) taken orally once daily for 21 days followed by 7 COC-free days. Treatment Period A: COC containing taken orally once daily for 21 days followed by 7 COC-free days. Treatment Period B: COC taken orally once daily for 21 days, with once daily oral 200 mg AQX-1125 (2 x 100 mg tablets) co-administered from Day 13 to 21, followed by 7 COC-free days |
Investigational Drug
COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Maximum observed plasma concentration (Cmax) of COC taken with AQX-1125
Tijdsspanne: 8 Weeks (from start of treatment period A to completion of treatment period B)
|
To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC
|
8 Weeks (from start of treatment period A to completion of treatment period B)
|
|
Time to attain maximum observed plasma concentration (tmax) of COC taken with AQX-1125
Tijdsspanne: 8 Weeks (from start of treatment period A to completion of treatment period B)
|
To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC
|
8 Weeks (from start of treatment period A to completion of treatment period B)
|
|
Area under the plasma concentration-time curve up to 24 hours (AUC0-24) of COC taken with AQX-1125
Tijdsspanne: 8 Weeks (from start of treatment period A to completion of treatment period B)
|
To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC
|
8 Weeks (from start of treatment period A to completion of treatment period B)
|
|
Terminal elimination rate constant (Kel) of COC taken with AQX-1125
Tijdsspanne: 8 Weeks (from start of treatment period A to completion of treatment period B)
|
To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC
|
8 Weeks (from start of treatment period A to completion of treatment period B)
|
|
Terminal elimination half-life (t1/2) of COC taken with AQX-1125
Tijdsspanne: 8 Weeks (from start of treatment period A to completion of treatment period B)
|
To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC
|
8 Weeks (from start of treatment period A to completion of treatment period B)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Safety and tolerability of AQX-1125 200 mg qd administered with the COC
Tijdsspanne: 16 weeks (from start of pre-treatment cycle 1 to completion of treatment period B)
|
Safety and tolerability will be assessed by the severity and frequency of adverse events, which will include any abnormal clinically significant vital signs, laboratory tests, electrocardiogram and physical examination findings
|
16 weeks (from start of pre-treatment cycle 1 to completion of treatment period B)
|
|
Maximum observed plasma concentration (Cmax) of AQX-1125 taken with COC
Tijdsspanne: 8 Weeks (from start of treatment period A to completion of treatment period B)
|
To assess the PK of 200 mg AQX-1125 qd when given together with the COC
|
8 Weeks (from start of treatment period A to completion of treatment period B)
|
|
Time to attain maximum observed plasma concentration (tmax) of AQX-1125 taken with COC
Tijdsspanne: 8 Weeks (from start of treatment period A to completion of treatment period B)
|
To assess the PK of 200 mg AQX-1125 qd when given together with the COC
|
8 Weeks (from start of treatment period A to completion of treatment period B)
|
|
Area under the plasma concentration-time curve up to 24 hours (AUC0-24) of AQX-1125 taken with COC
Tijdsspanne: 8 Weeks (from start of treatment period A to completion of treatment period B)
|
To assess the PK of 200 mg AQX-1125 qd when given together with the COC
|
8 Weeks (from start of treatment period A to completion of treatment period B)
|
|
Terminal elimination rate constant (Kel) of AQX-1125 taken with COC
Tijdsspanne: 8 Weeks (from start of treatment period A to completion of treatment period B)
|
To assess the PK of 200 mg AQX-1125 qd when given together with the COC
|
8 Weeks (from start of treatment period A to completion of treatment period B)
|
|
Terminal elimination half-life (t1/2) of AQX-1125 taken with COC
Tijdsspanne: 8 Weeks (from start of treatment period A to completion of treatment period B)
|
To assess the PK of 200 mg AQX-1125 qd when given together with the COC
|
8 Weeks (from start of treatment period A to completion of treatment period B)
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- AQX-1125-104
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .